CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,219 enrolled
Drug / intervention
Trajenta tabletdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01707147
NCT01707147N/ACompleted
CompareCT.gov

A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study)

Boehringer Ingelheim·observational·Posted Oct 16, 2012·Updated Jan 11, 2019

In Brief

An observational study evaluating Trajenta tablet for Diabetes Mellitus, Type 2. Completed, enrolled 3,219 participants across 1 site.

Detailed Summary

The aim of this study is to monitor safety and efficacy of treatment with linagliptin in Korean patients with type 2 diabetes mellitus in routine clinical settings.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesSouth Korea
CollaboratorsEli Lilly and Company

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 16, 2012
Enrollment StartNov 16, 2012
Primary CompletionJul 11, 2017
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 13.7 years ago

Interventions

Trajenta tabletdrug

Linagliptin